These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1125 related articles for article (PubMed ID: 2129155)

  • 1. Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type I plasminogen activator inhibitor.
    Sordat B; Reiter L; Cajot JF
    Cell Differ Dev; 1990 Dec; 32(3):277-85. PubMed ID: 2129155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse L cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.
    Cajot JF; Schleuning WD; Medcalf RL; Bamat J; Testuz J; Liebermann L; Sordat B
    J Cell Biol; 1989 Aug; 109(2):915-25. PubMed ID: 2503527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
    Baker MS; Bleakley P; Woodrow GC; Doe WF
    Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
    Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg
    Blood; 1996 Jun; 87(11):4718-22. PubMed ID: 8639841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
    Meissauer A; Kramer MD; Hofmann M; Erkell LJ; Jacob E; Schirrmacher V; Brunner G
    Exp Cell Res; 1991 Feb; 192(2):453-9. PubMed ID: 1899072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
    Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
    J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
    Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
    He C; He P; Liu LP; Zhu YS
    J Cancer Res Clin Oncol; 2001; 127(3):180-6. PubMed ID: 11260863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.
    Cajot JF; Bamat J; Bergonzelli GE; Kruithof EK; Medcalf RL; Testuz J; Sordat B
    Proc Natl Acad Sci U S A; 1990 Sep; 87(18):6939-43. PubMed ID: 2169614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
    Tang L; Han X
    Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
    Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
    Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
    Sipley JD; Alexander DS; Testa JE; Quigley JP
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
    Hearing VJ; Law LW; Corti A; Appella E; Blasi F
    Cancer Res; 1988 Mar; 48(5):1270-8. PubMed ID: 2963689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
    Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
    Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.
    Liu G; Shuman MA; Cohen RL
    Int J Cancer; 1995 Feb; 60(4):501-6. PubMed ID: 7829264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.
    Estreicher A; Mühlhauser J; Carpentier JL; Orci L; Vassalli JD
    J Cell Biol; 1990 Aug; 111(2):783-92. PubMed ID: 2166055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rat alveolar epithelial cells concomitantly express plasminogen activator inhibitor-1 and urokinase.
    Gross TJ; Simon RH; Kelly CJ; Sitrin RG
    Am J Physiol; 1991 Apr; 260(4 Pt 1):L286-95. PubMed ID: 1902065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.